Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Neuroone Medical Technologies (NMTC) over the last 12 years, with Q4 2025 value amounting to $552332.0.

  • Neuroone Medical Technologies' Accounts Payables fell 2581.42% to $552332.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $552332.0, marking a year-over-year decrease of 2581.42%. This contributed to the annual value of $1.0 million for FY2025, which is 183.02% down from last year.
  • According to the latest figures from Q4 2025, Neuroone Medical Technologies' Accounts Payables is $552332.0, which was down 2581.42% from $1.0 million recorded in Q3 2025.
  • Neuroone Medical Technologies' Accounts Payables' 5-year high stood at $1.0 million during Q3 2024, with a 5-year trough of $296410.0 in Q2 2021.
  • Moreover, its 5-year median value for Accounts Payables was $751892.5 (2024), whereas its average is $702374.0.
  • Its Accounts Payables has fluctuated over the past 5 years, first skyrocketed by 19499.43% in 2023, then crashed by 3839.61% in 2025.
  • Over the past 5 years, Neuroone Medical Technologies' Accounts Payables (Quarter) stood at $703718.0 in 2021, then rose by 22.44% to $861638.0 in 2022, then dropped by 11.8% to $760000.0 in 2023, then decreased by 2.04% to $744525.0 in 2024, then fell by 25.81% to $552332.0 in 2025.
  • Its Accounts Payables was $552332.0 in Q4 2025, compared to $1.0 million in Q3 2025 and $467734.0 in Q2 2025.